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Abstract
Background: Measuring functional status in palliative care may help clinicians to assess a patient’s prognosis,
recommend adequate therapy, avoid futile or aggressive medical care, consider hospice referral, and evaluate provided
rehabilitation outcomes. An optimized, widely used, and validated tool is preferable. The Palliative Performance Scale
Version 2 (PPSv2) is currently one of the most commonly used performance scales in palliative settings. The aim of this
study is the psychometric validation process of a Polish translation of this tool (PPSv2-Polish).
Methods: Two hundred patients admitted to a free-standing hospice were evaluated twice, on the first and third day,
for test-retest reliability. In the first evaluation, two different care providers independently evaluated the same patient
to establish inter-rater reliability values. PPSv2-Polish was evaluated simultaneously with the Karnofsky Performance
Score (KPS), Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS), and Barthel Activities of Daily
Living (ADL) Index, to determine its construct validity.
Results: A high level of full agreement between test and retest was seen (63%), and a good intra-class correlation
coefficient of 0.85 (P < 0.0001) was achieved. Excellent agreement between raters was observed when using PPSv2-
Polish (Cohen’s kappa 0.91; P < 0.0001). Satisfactory correlations with the KPS and good correlations with ECOG PS and
Barthel ADL were noticed. Persons who had shorter prognoses and were predominantly bedridden also had lower
scores measured by the PPSv2-Polish, KPS and Barthel ADL. A strong correlation of 0.77 between PPSv2-Polish scores
and survival time was noted (P < 0.0001). Moderate survival correlations were seen between KPS, ECOG PS, and Barthel
ADL of 0.41; − 0.62; and 0.58, respectively (P < 0.0001).
Conclusion: PPSv2-Polish is a valid and reliable tool measuring performance status in a hospice population and can be
used in daily clinical practice in palliative care and research.
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Background
Functional decline, in addition to symptom burden, results
in increased dependency on others and negatively affects a
patient’s quality of life. Most people want to remain
symptom-free and to maintain as much independence as
possible until the latest phases of life. The importance of
measuring functional status in palliative care is incontest-
able. It may help clinicians to assess a patient’s prognosis,
recommend further oncological therapy, avoid futile, ag-
gressive medical care, consider hospice referral and evalu-
ate provided rehabilitation outcomes. All measuring tools
may have disadvantages, and an optimal one, which may
also be used in monitoring the outcomes of physical ther-
apy, specifically in palliative care, is lacking [1]. The Pallia-
tive Performance Scale version 2 (PPSv2) is currently one
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of the most commonly used performance scales in pallia-
tive settings. It was developed by the Victoria Hospice
Society as a modification of the Karnofsky Performance
Scale in 1996 [2] and validated later [3]. It has also been
demonstrated that PPSv2 correlates with patients’ survival
time [4]. Although occasionally used in Poland, it has not
been validated yet. It is reasonable to disseminate know-
ledge among professionals and promote its use through
cultural adaptation.
Methods
Aim
The aim of this study is the cross cultural adaptation
and psychometric validation of a Polish translation of
PPSv2 tool (PPSv2-Polish).
Design
We obtained agreement and guidelines for the transla-
tion process from the Victoria Hospice Society, the
owner of the tool.
The tool translation and back-translation were done in
cooperation of three palliative care centers: St. Lazarus
Hospice in Krakow, Medical University of Warsaw
(Poland), and Jagiellonian University Medical College,
Krakow, Poland.
The testing and retesting of PPSv2-Polish was per-
formed by the hospice care team at St. Lazarus Hospice
in Krakow (Poland).
Patient characteristics, including gender, age, primary
diagnosis, and disease stage based on the Gold Standard
Framework needs based coding (GSF; see Table 1) [5]
assessed by the attending physician, were obtained from
medical records. All participants were evaluated twice,
on the first and third day, for test-retest reliability by the
same member of the hospice care team at St. Lazarus
Hospice in Krakow (Poland) (a trained and experienced
palliative care nurse, psychologist, or physiotherapist),
who cared for the patient. Additionally, on the first
evaluation, two different care providers (each time by
different types of professionals) independently evaluated
the same patient to establish inter-rater reliability values.
Each patient’s evaluation encompassed the PPSv2-Polish,
which was compared simultaneously with 3 additional
performance scales, considered the gold standard [6], to
accomplish its external construct validity.
Participants
Among 223 patients consecutively admitted to an in-
patient hospice (between September 1st and November
30th 2019), 200 (aged ≥18 years), who were Polish native
speakers whose performance status was unlikely to change
significantly during the nearest 3 days according to the at-
tending physician, were recruited and enrolled in the study.
Measures
Palliative performance scale version 2 (PPSv2)
The PPS provides a functional assessment of a patient’s
ambulation, activity level, evidence of disease, self-care,
food/fluids intake, and level of consciousness. The PPS
has 11 categories, from 100% (full mobile and healthy)
to 0% (dead) in decrements of 10%. In 2006, PPS version
2 (PPSv2) was introduced after clarification of instruc-
tions for its use [7].
PPSv2-polish translation process
A modified combined translation technique [8] of PPSv2
into Polish was applied, which consisted of 1) independent
forward translations by a physician, a psychologist and a
Polish native speaker, 2) team discussion on identified dif-
ferences between these 3 versions until agreement, 3)
independent backward translations by a physician, a
psychologist and a native English speaker, and 4) second
team discussion on any differences between the original
and back-translated versions until all agreed that the two
versions were semantically identical (Fig. 1).
This method followed the Victoria Hospice translation
guidelines sent to the authors. The discussed back-
translated version was then preliminarily tested in the
hospice on 20 patients to obtain the final version of the
PPSv2 (PPSv2-Polish – see Additional file 1). The imple-
mentation process encompassed education of the med-
ical staff participating in this study during one training
session, based on the Victoria Hospice Society instruc-
tions sent to the authors, giving the opportunity to get
feedback from the team members.
Karnofsky performance score (KPS)
The KPS ranking is an 11-point scale and runs from
100% - perfect health, to 0% - dead. While first pub-
lished in 1948 [9] to evaluate the ability to survive
chemotherapy for cancer, it has recently undergone sev-
eral evaluation adjustments [10]. The KPS provides great
consistency of ratings by different oncology professionals
[11]. It may also serve as a life survival predictor [12].
Hovewer, it has not been validated in Poland yet.
Eastern cooperative oncology group (ECOG) performance
status (ECOG PS)
This scale, also called the World Health Organization
(WHO) score, was published in its current form by
Table 1 GSF Needs Based Coding
GSF Code Disease progression Expected prognosis
A Stable from diagnosis Years
B Unstable / advanced disease Months
C Deteriorating Weeks
D Final days Days
Abbreviations: GSF Gold Standard Framework
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ECOG in 1982 [13] to assess a patient’s level of func-
tioning in terms of the ability to care for himself, daily
activity, and physical ability, in order to measure the im-
pact of the disease/treatment on performance status. It
has a good intra and interobserver agreement in cancer
patients’ performance status assessment [14]. It consists
of 6 categories, from 0 - fully active, to 5 - dead, and is
simpler to use, may be clinically preferable in compari-
son to the KPS, [15] and is widely used in the literature,
yet not validated in Poland.
Barthel activities of daily living (ADL) index
This “simple index of independence” was published in
1965 for measuring the improvement during rehabilitation
of the chronically ill" [16]. The original version was modi-
fied in 1988 to a 20 point scale that measures in incre-
ments of 1 point: from 0 - fully dependent, to 20 - fully
independent [17]. The final score can be multiplied by 5
to obtain a 100 point score, and it is proposed that scores
of 0–20 indicate “total” dependency, 21-60 indicate “se-
vere” dependency, 61–90 indicate “moderate” dependency,
and 91–99 indicates “slight” dependency. It is already
widely used as the measurement of daily living activities
and has become a standard measure of physical disability
in practice [18]. Ten categories are assessed: feeding,
grooming, bathing, dressing, toilet use, presence of fecal
incontinence, presence of urinary incontinence, transfers
(e.g., moving from wheelchair to bed), walking on an even
surface (or propelling a wheelchair if unable to walk), and
ascending and descending stairs. This scale has been
widely used, however, has not yet been adapted in Poland.
Statistical analysis
We summarized the baseline demographics using descrip-
tive statistics and medians with interquartile ranges (IQR)
in non-normally (according to Shapiro-Wilk test) distrib-
uted ordinal quantitative data. A Wilcoxon signed-rank
test was used to compare test-retest of ordinal data in one
sample in test-retest and inter-rater comparison. Non-
parametric data within subgroups of patients were com-
pared using a Mann-Whitney U test. The strength of the
relationship between the test-retest variables, and between
the tools scores and survival time were calculated with the
Spearman’s rank correlation coefficient. The inter-rater re-
liability was estimated using Cohen’s kappa statistics. Data
were analyzed using STATISTICA 13.0 (TIBCO Software
Inc. 2017) data analysis software. A P-value of < 0.05 was
considered as the level for statistical significance. The sam-
ple size for this survey was based on general guidelines for
conducting qualitative research [19] As there are no abso-
lute rules for the sample size needed to validate a question-
naire a fair size of 200 patients was chosen.
Results
In all cases the hospice staff were able to complete the
evaluation according to the study protocol (no missing
values, a response rate of 100%), and they assessed the tool
as easy to use and not excessively time consuming. This
indicates that the PPSv2-Polish appeared a feasible and
acceptable assessment tool in their practice. At the begin-
ning of implementation, in the training phase of this
study, two out of six team members made observations
that the 5-steps of PPSv2-Polish assessment was a bit
Fig. 1 Graphical representation of translation process of PPSv2-Polish
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prolonged, in comparison with 1-step assessment of KPS
or ECOG PS. All participating staff emphasized the need
for observation of a patient for a reasonable period of time
to accurately asses his or her true “capable” functions
based on the “observed” ones, during the day shift.
The majority of patients were aged, had advanced can-
cer, with short (weeks) prognosis according to GSF, and
finally died at the hospice (Table 2).
Test-retest reliability
The median PPSv2-Polish value within the first meas-
urement was 30 (IQR 10), which correlated with the data
obtained 2 days later (median 30; IQR 20) by the same
care provider. We achieved a high level of full agreement
between test and retest (63%) and a good intra-class cor-
relation coefficient of 0.85 (P < 0.0001).
Inter-rater reliability
An excellent PPSv2-Polish agreement between raters
was observed (Cohen’s kappa 0.91; P < 0.0001). A high
level (94–99%) of full agreement between raters was ob-
served, with the exception of ECOG PS, where this
agreement was not achieved (Table 3).
Criterion validity
Satisfactory correlations with the KPS and good correlation
with ECOG PS and Barthel ADL were noticed (Table 4).
Known-group validity
Persons who had shorter prognosis and were predomin-
antly bedridden also had lower scores measured by the
PPSv2-Polish, KPS and Barthel ADL (Table 5).
Survival estimation
A strong correlation between each category assessed in
PPSv2-Polish and survival time was noted (0.77; P <
0.0001). Median survival time (IQR) in GSF B, C and D
group was respectively 37 (21.3), 23 (13.0) and 12 (23.5)
days. Moderate survival correlations were observed be-
tween KPS, ECOG PS, and Barthel ADL Index scores
(0.41, − 0.62, and 0.58, respectively; P < 0.0001).
Discussion
The PPSv2-Polish which was created with a combined
translation technique appears to be a valuable clinical
assessment tool in the hospice setting within the Polish
population of cancer patients. The translation and
implementation process and training of experienced
palliative care medical staff proceeded without any par-
ticular difficulties. The team members reported that the
PPSv2-Polish tool was clear and easy, although a bit
time consuming to use in daily practice, and it required
observation of a patient for a significant period of time
(e.g. through a whole shift) to assess the potential cap-
ability of evaluated functions. When comparing various
Table 2 Patient characteristics and description
Parameter n = 200 %
Median age in years (IQR) 72.5 (16.0)
Females 144 72.0
Primary cancer tumor site
Digestive 34 17.0
Respiratory 35 17.5
Genitourinary 22 11.0
Breast 21 10.5
Others 67 33.5
Nonmalignant diseases 21 10.5
Stage – prognosis (GSF)
B – Stable/months 32 16.0
C – Progressing/weeks 141 70.5
D – Last days 27 13.5
ECOG PS
1 3 1.5
2 23 11.5
3 41 20.5
4 133 66.5
Died
In 1–30 days 117 58.5
In > 30 days 58 29.0
Discharged 25 12.5
Abbreviations: IQR interquartile range, GSF Gold Standards Framework, ECOG PS
Eastern Cooperative Oncology Group Performance Status,
Table 3 Inter-rater agreement of scales used in the study
Scales Rater #1 Rater #2 % full
agreement
P
Median IQR Median IQR
PPSv2-Polish 30.0 10.0 30.0 10.0 94.0 0.13
KPS 45.0 10.0 40.0 10.0 99.0 0.18
ECOG PS 4.0 1.0 4.0 10.0 95.5 0.54
Barthel ADL 5.0 22.5 5.0 22.5 83.0 0.001
P Wilcoxon signed-rank test,
Abbreviations: IQR interquartile range, PPSv2-Polish Polish translation of the
Palliative Performance Scale Version 2, KPS Karnofsky Performance Score, ECOG
PS Eastern Cooperative Oncology Group Performance Status, ADL Activities of
Daily Living Index.
Table 4 Correlations between the scales used in the study
KPS ECOG Barthel ADL
PPSv2-Polish 0.69* −0.81* 0.75*
KPS −0.57* 0.68*
ECOG PS −0.73*
* Spearman’s Rho P < 0.001, Abbreviations: PPSv2-Polish Polish translation of the
Palliative Performance Scale Version 2, KPS Karnofsky Performance Score, ECOG
PS Eastern Cooperative Oncology Group Performance Status, ADL Activities of
Daily Living
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performance tools, it appears that no one is statistically
superior to others in terms of inter-rater reliability [20].
The ECOG PS or KPS are often used in determining
eligibility for clinical trials. However, there could be a
substantial disagreement in the assessment of perform-
ance status between oncologists, even when using as
simple a tool as the ECOG PS [21]. Patients’ age, pref-
erences and socio-economic background may also in-
fluence the assessment. Numerous studies confirmed
good correlations of KPS, ECOG PS, and PPS tools, and
meta-analysis favors KPS as descriptively better [20].
Authors of the original version of the PPSv2 noticed
that in contrary to the KPS, this scale does not focus on
the need for hospitalization (which is of poor definability
and does not help in defining performance) but instead as-
sesses food/fluid intake and level of consciousness [2]. The
ambiguity of the KPS assessment when patients were bed-
ridden (KPS ≤ 40%) led to scale modification in Australia
[22]. PPSv2 usage assumes a 5-step assessment, which can
be problematic at the beginning, but after training may be
more comprehensive and accurate. Both KPS and PPSv2
scales need standardized, appropriate instructions regarding
performance evaluation. Compared with the 5-point ECOG
PS, the 11-point PPSv2 seems to be a more precise tool, es-
pecially for lower performance statuses. This phenomenon
was also affirmed in our observations, where the ECOG PS
did not achieve significant reliability between the scoring of
different types of professionals.
The high level of agreement with a very good correl-
ation in serial scoring by one rater in a 2 days interval
appeared better than in another study with 2 weeks be-
tween consecutive assessments [3]. The chosen interval
of 2 days between assessments allowed for an optimal
period not to recall the first scoring, yet not too long to
allow changes in performance in most cases.
The excellent inter-rater concordance observed in this
study was higher than in an updated meta-analysis recently
published [20]. The explanation of this phenomenon partially
could be explained by the careful inclusion of rating staff,
who attended to patients for several hours daily and had a
great understanding of their mobility and functionality [11].
The strength of this study was the high inter-rater
agreement each time between different professionals
(nurse, psychologist, or physiotherapist) took part in the
assessment. There are inconsistencies in the evaluation
of a patient’s performance status using the same tool by
different types of professionals (doctors rated patients as
healthier than nurses using the PPSv2 scale), and it may
be explained by different amounts of time spent with the
evaluated person [11]. However, even research asistants
rated patients simillar to physicians (oncologists or radi-
ation therapists) in one study [23]. Optimally, it should
be advised to score patients within interdisciplinary team
meetings to gain a more accurate assessment [24].
Our study legitimizes the usage of the PPSv2-Polish in
prognostication of patients with advanced cancer, which
is in line with previous studies [4, 7]. The strongest cor-
relation between the PPSv2-Polish and survival time
among the analysed tools was remarkable, and as to the
best of our knowledge it was not published earlier. In
another recent study of advanced cancer patients with
prognosis in terms of weeks, the PPSv2 assessment was
as accurate as subjective clinical survival predictions
[25]. The similarity between the subjective prognosis as-
sessment of the attending physician, expressed by GSF
staging, and the PPSv2 scoring in our observations legiti-
mizes the good responsiveness of this newly validated
tool to patients’ changing prognosis and physical con-
dition. This finding could be explained by the strong
relationship between the hospice staff and the patient,
as this factor was described to have an impact on ac-
curacy [26].
This study was not without limitations. First, the ma-
jority of patients recruited presented a low performance
status, were mostly sitting or bedridden, and were not
representative for the whole palliative population. Sec-
ondly, only in-patient subjects were recruited and most
of the unstable patients were excluded due to the test-
retest requirements.
Conclusion
The Polish version of PPSv2 is a valid and reliable tool
measuring performance status in a hospice population,
which can be used in daily clinical practice in palliative
care, research, and prognostication.
Table 5 Responsiveness of the scales
Scales GSF A-B n = 32 GSF C-D n = 168 P ECOG 1–2 n = 26 ECOG 3–4 n = 174 P
Median IQR Median IQR Median IQR Median IQR
PPSv2-Polish 50.0 15.0 30.0 10.0 * 60.0 20.0 30.0 10.0 *
KPS 60.0 15.0 40.0 10.0 * 60.0 10.0 40.0 10.0 *
Barthel ADL 42.5 40.0 5.0 7.5 * 45.0 60.0 5.0 10.0 *
Median scores of each scale obtained within the known subgroups of longer (GSF A-B) and shorter (GSF C-D) prognosis and also within higher (ECOG PS 1–2) and
lower (ECOG PS 3–4) performance status. * P < 0.00001, Mann-Whitney U test
Abbreviations: GSF Gold Standard Framework, ECOG Eastern Cooperative Oncology Group, PPSv2-Polish Polish translation of the Palliative Performance Scale
Version 2, KPS Karnofsky Performance Score, ECOG PS Eastern Cooperative Oncology Group Performance Status, ADL Activities of Daily Living Index.
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